Search clinical trials for: SCH 39641

Total 2345 results

ALK-Abelló A/S

Completed

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Allergy
ALK-Abelló A/S

Completed

Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)

Allergy | Rhinitis | Conjunctivitis | Rhinoconjunctivitis
ALK-Abelló A/S

Completed

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Conjunctivitis | Rhinitis; Allergic, With Asthma
ALK-Abelló A/S

Completed

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)

Rhinitis, Allergic | Conjunctivitis
ALK-Abelló A/S

Completed

Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)

Rhinitis, Allergic, Seasonal
University Hospitals Cleveland Medical Center
University of Pittsburgh; The Cleveland Clinic; Duke University; Case Western Reserve... and other collaborators

Recruiting

Patient-Centered Outcomes in the Surgical Treatment of Uterovaginal Prolapse (PREMIER)

Uterine Prolapse

United States
Merck Sharp & Dohme LLC

Completed

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

Bladder Neoplasms
Merck Sharp & Dohme LLC

Completed

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Primary Hypercholesterolemia | Mixed Hyperlipidemia
Vertex Pharmaceuticals Incorporated
ViroChem Pharma

Completed

A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.

Hepatitis C, Chronic

Canada
National Cancer Institute (NCI)

Active, not recruiting

Dinaciclib in Treating Patients With Stage IV Melanoma

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Lentigo Maligna Melanoma | Mucosal Melanoma | Acral Lentiginous Melanoma | Cutaneous Nodular Melanoma | Low-CSD Melanoma

United States
M.D. Anderson Cancer Center
Schering-Plough

Withdrawn

SCH-900105 in Recurrent Glioblastoma

Glioblastoma
Merck Sharp & Dohme LLC

Withdrawn

Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)

Asthma
Merck Sharp & Dohme LLC

Completed

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Solid Tumors | Leukemia, Lymphocytic, Chronic. B-Cell
ALK-Abelló A/S

Completed

A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)

Conjunctivitis | Rhinitis Allergic
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED)

Obesity | Overweight | Body Weight
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2) (GO-MORE)

Arthritis, Rheumatoid
Merck Sharp & Dohme LLC

Completed

A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)

Psychosis
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Asthma
Merck Sharp & Dohme LLC

Terminated

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)

HIV Infections | Acquired Immunodeficiency Syndrome
Merck Sharp & Dohme LLC

Completed

Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)

HIV Infections | Acquired Immunodeficiency Syndrome
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Schering-Plough

Completed

SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy

HIV Infections | Meningitis, Cryptococcal

United States
UConn Health

Active, not recruiting

Sickle Cell Hemoglobinopathies and Bone Health

Sickle Cell Disease | Sickle Cell Trait

United States
Merck Sharp & Dohme LLC

Completed

SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)

Ovarian Cancer | Fallopian Tube Cancer | Metastatic Cancer | Primary Peritoneal Cavity Cancer
Merck Sharp & Dohme LLC

Completed

Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887)

Cough
Merck Sharp & Dohme LLC

Completed

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

Alzheimer's Disease
Merck Sharp & Dohme LLC

Completed

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

Depression | Psychotic Disorders | Depressive Disorders
Schering-Plough

Completed

A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)

Nausea | Vomiting
Merck Sharp & Dohme LLC

Completed

A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)

Opiate Dependence | Substance Dependence | Drug Dependence
Merck Sharp & Dohme LLC

Completed

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
Merck Sharp & Dohme LLC
Integrated Therapeutics Group

Completed

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Liver Cirrhosis | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Withdrawn

An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN) (PEGIMPACT)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) (PRACTICE)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Adherence to Treatment With PegIntron Pen Plus Rebetol in Treatment-naïve Adult Patients With Hepatitis C in Romania (Study P04247)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

Hepatitis C, Chronic
University of Utah

Completed

Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic

Oncology

United States
Merck Sharp & Dohme LLC

Completed

Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) (APEGIN)

Hepatitis C | Hepatitis C, Chronic
National Cancer Institute (NCI)

Completed

Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors

Brain and Central Nervous System Tumors
Merck Sharp & Dohme LLC

Terminated

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PROVIDE)

Hepatitis C, Chronic
National Cancer Institute (NCI)

Completed

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States, Singapore

3

Subscribe